ALRN-6924 + cyclophosphamide + docetaxel + doxorubicin

This is a combination regimen consisting of ALRN-6924, cyclophosphamide, docetaxel, and doxorubicin. ALRN-6924 is a first-in-class cell-permeating stapled α-helical peptide that mimics the N-terminal domain of the p53 tumor suppressor protein. It binds with high affinity to both MDM2 and MDMX (also known as MDM4), endogenous inhibitors of p53, thereby reactivating p53 signaling in cells with wild-type TP53. This leads to cell cycle arrest or apoptosis in cancer cells and can also be used at lower doses to transiently arrest the cell cycle in healthy tissues for chemoprotection[1][3][6]. Cyclophosphamide is an alkylating agent that crosslinks DNA leading to apoptosis; docetaxel is a taxane that stabilizes microtubules inhibiting mitosis; doxorubicin intercalates into DNA and inhibits topoisomerase II causing DNA damage. The combination has been studied particularly for its potential to reduce chemotherapy-induced toxicities (such as neutropenia) by using ALRN-6924 as a chemoprotective agent during standard cytotoxic chemotherapy regimens[1][3][4].

Other names

ALRN-6924 plus TAC regimenALRN6924 plus TAC regimenALRN 6924 plus TAC regimenALRN-6924 + doxorubicin + cyclophosphamide + docetaxel